The purpose of this study is to investigate effects of BMS-986165 on blood levels of methotrexate given as a single dose in healthy male patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
PRA Health Sciences
Groningen, Netherlands
Maximum observed plasma concentration (Cmax)
Time frame: Approximately 14 days
Time to attain maximum observed plasma concentration (Tmax)
Time frame: Approximately 14 days
Area under the plasma concentration-time curve up to time T, where T is the last point with concentrations above the lower limit of quantitation [AUC(0-T)]
Time frame: Approximately 14 days
Area under the plasma concentration-time curve from time 0 to infinity [AUC(INF)]
Time frame: Approximately 14 days
Terminal elimination rate constant (kel)
Time frame: Approximately 14 days
Terminal elimination half life, calculated as 0.693/kel (T-HALF)
Time frame: Approximately 14 days
Apparent oral clearance (CL/F)
Time frame: Approximately 14 days
Incidence of adverse events (AEs)
Time frame: Approximately 19 days
Incidence of serious adverse events (SAEs)
Time frame: Approximately 19 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.